{"filings":[{"id":746676,"accession_number":"0001193125-26-248280","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K/A","filed_at":"2026-05-29T20:10:16+00:00","items":["5.07"],"status":"ready","headline":"Bruker shareholders approve all three proposals at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Laura A. Francis, John J. Phillips, and Hermann F. Requardt as Class II directors with >95% of votes cast.","Advisory vote on 2025 executive compensation passed with 127,190,553 for, 5,748,270 against, 60,390 abstain.","Ratification of PricewaterhouseCoopers LLP as auditor for FY2026 approved (138,544,738 for, 618,216 against, 29,744 abstain)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":583358,"accession_number":"0001193125-26-234630","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2026-05-21T20:44:54+00:00","items":["5.07"],"status":"ready","headline":"Bruker stockholders elect three Class II directors, approve compensation, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Laura A. Francis, John J. Phillips, and Hermann F. Requardt as Class II directors for three-year terms.","Advisory vote on 2025 named executive officer compensation passed with 127.2M for, 5.7M against.","Ratified PricewaterhouseCoopers LLP as independent auditor for fiscal 2026 with 138.5M for, 0.6M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":471120,"accession_number":"0001193125-26-226767","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2026-05-15T20:15:17+00:00","items":["8.01"],"status":"ready","headline":"Bruker declares quarterly dividend of $0.05 per share","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly cash dividend of $0.05 per common share declared.","Declared on May 14, 2026, by Board of Directors.","Payable July 7, 2026, to shareholders of record on June 22, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91352,"accession_number":"0001193125-26-207498","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bruker Q1 revenue $823.4M (+2.7% reported, -4.4% organic); GAAP EPS $0.02","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1-26 GAAP diluted EPS $0.02 (vs $0.11 YoY); non-GAAP diluted EPS $0.31 (vs $0.47 YoY).","BSI segment bookings grew high-single digits organically YoY; book-to-bill >1.0x for 3rd consecutive quarter.","FY2026 guidance reaffirmed: revenue $3.57-$3.60B (4-5% reported, 1-2% organic); non-GAAP EPS $2.10-$2.15.","GAAP operating income $10.2M vs $31.8M YoY; non-GAAP operating margin 10.2% vs 12.7% YoY.","BEST segment revenue $66.9M (+12.8% reported, +3.0% organic); BSI revenue $759.8M (+2.1% reported, -5.0% organic)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":823400000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91351,"accession_number":"0001193125-26-187102","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bruker declares quarterly dividend on 6.375% Mandatory Convertible Preferred Stock","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly dividend of $3.9844 per share on 6.375% Mandatory Convertible Preferred Stock (BRKRP).","Dividend payable June 1, 2026, to holders of record at close of business on May 15, 2026.","Dividend declared on April 28, 2026; no change to common stock dividend."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91350,"accession_number":"0001193125-26-151220","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bruker BioSpin President Falko Busse to depart; separation includes ~$1M severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Falko Busse, Ph.D., to step down as President of Bruker BioSpin; duties transition May 1, 2026, employment ends Oct 31, 2026.","Separation agreement provides approximately $1,020,351 in severance, prorated bonus, and unused vacation payout.","Unvested equity awards as of Oct 31, 2026 will be forfeited per plan provisions.","Agreement includes non-compete, non-solicitation, non-disparagement, and confidentiality covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91349,"accession_number":"0001193125-26-135660","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bruker appoints QIAGEN CEO Thierry Bernard to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thierry L. Bernard appointed to Bruker's Board effective April 1, 2026; board expanded to 12 directors.","Bernard is CEO of QIAGEN N.V. (NYSE: QGEN), set to step down upon successor appointment; brings life-science tools expertise.","He previously served 15 years at bioMérieux including Corporate VP Global Commercial Operations, Investor Relations, and Greater China.","Bernard also sits on Neogen Corporation (NASDAQ: NEOG) board and chairs AdvaMedDx trade association."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101372,"accession_number":"0001193125-26-061500","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Bruker director Friend to retire; Phillips reclassified to Class II; declares $0.05 quarterly dividend","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Cynthia M. Friend will not stand for re-election at the 2026 Annual Meeting; she continues as director until then.","Jack Phillips stepped down as Class III director and was re-elected as Class II director; service deemed continuous since Jan 1, 2026.","Board declared $0.05 per share quarterly common dividend, payable April 7, 2026 to holders of record March 23, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101371,"accession_number":"0001193125-26-047618","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bruker Q4 revenue flat, FY25 GAAP loss $0.15; guides FY26 non-GAAP EPS up 15-17%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4-25 revenues $977.2M, flat YoY (-0.2%), organic decline 5.1%; GAAP EPS $0.10, non-GAAP EPS $0.59.","FY25 revenues $3.44B (+2.1% reported, -3.7% organic); GAAP diluted loss $(0.15), non-GAAP EPS $1.83.","FY25 included $127.2M goodwill/intangibles impairment and $77.4M restructuring charges.","FY26 guidance: revenues $3.57-3.60B (+4-5% reported, +1-2% organic); non-GAAP EPS $2.10-2.15 (+15-17% YoY).","FY26 EPS guidance includes ~$0.15 currency headwind (8%); organic decline expected in Q1-26, recovery in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":3436500000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101370,"accession_number":"0001193125-26-010106","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01"],"status":"ready","headline":"Bruker prelim Q4 2025 revenue $965-970M; FY26 outlook flat to low-single-digit organic growth","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 2025 preliminary revenue $965-970M; scientific instruments book-to-bill above 1.0.","FY 2026 outlook: organic revenue growth flat to up low-single digits vs. 2025.","Non-GAAP organic operating margins expected to expand 250-300 bps in FY26.","Non-GAAP EPS for FY26 expected to grow double-digits compared to FY25.","Forward-looking statements subject to final audit and adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117735,"accession_number":"0001193125-25-312106","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bruker appoints diagnostics industry veteran Jack Phillips to board, effective Jan 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jack Phillips appointed to Bruker board effective Jan 1, 2026, filling newly created 11th director seat.","Phillips previously President & CEO of Accelerate Diagnostics (2020-25) and Roche Diagnostics North America (2010-20).","CEO Laukien says addition is timely as Bruker broadens infectious disease diagnostics portfolio.","Phillips will serve until 2027 Annual Meeting; compensation consistent with other non-employee directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117734,"accession_number":"0001193125-25-261638","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bruker Q3 revenue $860.5M (-0.5% YoY); GAAP loss $0.41/share; cuts FY25 EPS guidance to $1.85-1.90","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 GAAP diluted loss per share $(0.41); non-GAAP diluted EPS $0.45 vs $0.60 a year ago.","Non-GAAP operating margin 12.3%, down from 14.9%; includes $119.4M goodwill/intangibles impairment and $34.5M restructuring.","FY2025 revenue guidance lowered to $3.41-3.44B (1-2% reported growth, organic decline 4-5%).","Non-GAAP EPS guidance cut to $1.85-1.90 from FY2024 $2.41, citing market weakness and higher share count.","Q3 organic bookings grew mid-single-digit YoY; BSI book-to-bill above 1.0; cost-savings target $100-120M for FY2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":2459300000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134182,"accession_number":"0001140361-25-034295","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Bruker closes $690M 6.375% mandatory convertible preferred stock offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 2.76M shares of Series A mandatory convertible preferred (BRKRP) at $250 liquidation preference per share, total $690M.","Net proceeds approx. $669.5M after underwriting discounts and expenses; full over-allotment exercised.","Mandatory conversion on Sept 1, 2028 into 6.9534–8.5179 shares of BRKR common per preferred share.","Cumulative dividends at 6.375% p.a., payable quarterly starting Dec 1, 2025; may be paid in cash or common stock.","Restricts common stock dividends and repurchases while preferred is outstanding unless all preferred dividends are paid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134181,"accession_number":"0000950170-25-101605","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bruker Q2 revenue $797M, -0.4% YoY; non-GAAP EPS $0.32, -38.5%; lowers FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $797.4M, organic -7.0% YoY from weak US academic and biopharma demand.","GAAP EPS $0.05; non-GAAP EPS $0.32, down 38.5% vs Q2 2024 $0.52.","BSI segment revenue $733.2M (organic -7.2%); BEST segment $66.3M (organic -4.8%).","FY2025 guidance cut: revenue $3.43-3.50B (2-4% reported growth), non-GAAP EPS $1.95-2.05 vs FY2024 $2.41.","Announced expanded cost initiative targeting $100-120M annual savings in FY2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":1598800000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134180,"accession_number":"0000950170-25-097082","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bruker pre-announces Q2 preliminary EPS $0.32-$0.34, down ~$0.19 YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q2 2025 revenue $795-$798M, roughly flat YoY reported; constant-currency revenue down ~3%.","Non-GAAP organic revenue declined ~7% YoY on weak academic demand and soft U.S. biopharma market.","Non-GAAP EPS expected $0.32-$0.34, down ~$0.19 YoY inclusive of $0.06 FX headwind.","Q2 2025 bookings reflect weak academic and biopharma demand; cost actions underway.","Final Q2 results and earnings call scheduled for August 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":1598800000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150951,"accession_number":"0000950170-25-079029","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Bruker stockholders approve 2026 Incentive Compensation Plan authorizing 12M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 2026 Plan with 12M shares authorized (6M new + ~5M carryover from 2016 Plan). Effective Feb 19, 2026.","Four Class I directors elected: Anderson, Laukien, Ornell, Packer; votes ranged from 89.5M to 116.8M for.","Advisory vote on 2024 named executive officer compensation passed: 108.8M for, 6M against.","Ratification of PricewaterhouseCoopers as independent auditor for FY 2025 approved: 131.6M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150950,"accession_number":"0000950170-25-071353","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bruker and 10x Genomics settle all global patent litigation with cross-license agreements","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement resolves all patent disputes between Bruker and 10x Genomics, including multiple litigations in US, Germany, and European Unified Patent Court.","All ongoing lawsuits and administrative proceedings will be withdrawn under global patent cross license agreements.","Bruker's CosMx and GeoMx spatial biology platforms no longer face litigation risk; company can focus on research.","No financial terms of settlement disclosed; parties entered into cross-license agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150949,"accession_number":"0000950170-25-064973","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bruker Q1 revenues up 11% but EPS falls; lowers FY2025 guidance on tariff and market headwinds","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenues $801.4M, up 11.0% YoY; GAAP diluted EPS $0.11, non-GAAP diluted EPS $0.47 (down 11.3% YoY).","BSI segment organic revenue grew 5.1% YoY; BEST segment revenue fell 18.9% YoY.","FY2025 revenue guidance lowered to $3.48-3.55B (organic growth 0-2%), non-GAAP EPS $2.40-2.48 (0-3% growth).","Management cites academic market and tariff headwinds; expects to mitigate slightly over half of the impact in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":801400000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150948,"accession_number":"0000950170-25-053032","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bruker pre-announces Q1 2025 revenue: $795M-$800M, ~10% YoY growth, beating outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q1 2025 revenue range $795M-$800M; reported growth ~10% YoY, low-double digit constant-exchange-rate growth.","Non-GAAP organic revenue growth low-single digits; BSI segment mid-single digit, BEST segment high-teens organic decline.","Results compare favorably to prior company outlook and are well ahead of consensus.","Final Q1 2025 financial results to be reported before market open on May 7, 2025, with conference call that day."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":801400000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169857,"accession_number":"0000950170-25-024543","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bruker appoints Laura Francis to Board of Directors; former Bruker CFO and current SI-BONE CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Laura Francis appointed as independent director of Bruker effective Feb 18, 2025, expanding Board to ten directors.","Francis is CEO of SI-BONE (SIBN) and former Bruker CFO; will serve until 2026 Annual Meeting and join Audit Committee.","No transactions requiring disclosure; compensation consistent with other non-employee directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169856,"accession_number":"0000950170-25-019332","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bruker Q4 revenue $979.6M (+14.6% YoY); FY 2025 guidance implies 11-13% EPS growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $979.6M (+14.6% YoY); organic +3.9%; GAAP EPS $0.09; non-GAAP EPS $0.76 (+8.6%).","FY 2024 revenue $3.37B (+13.6% YoY); GAAP EPS $0.76; non-GAAP EPS $2.41 (down 6.6% due to H1 M&A).","FY 2025 guidance: revenue $3.47-3.54B (3-5% reported, 5-7% CER); non-GAAP EPS $2.67-$2.72 (+11-13%).","Q4 non-GAAP operating margin 18.1% (flat YoY); organic margin gains offset M&A/FX headwinds.","BSI segment organic revenue +4.5% in Q4; BEST segment organic revenue -2.8% in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":3366400000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169855,"accession_number":"0000950170-25-006262","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bruker appoints Thomas Bures as CAO; base salary $415k, 2,972 RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas Bures appointed Chief Accounting Officer of Bruker, effective Jan 13, 2025.","Base salary of $415,000.04, bonus target 45%, and 2,972 RSUs vesting 25% annually over 4 years.","Previous SVP and CFO of Pieris Pharmaceuticals (2021-2024); over 20 years in finance.","No family relationships with executives or directors; no material interests in transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169854,"accession_number":"0000950170-25-004646","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01"],"status":"ready","headline":"Bruker sees Q4 2024 revenue of $970M-$980M; 2025 outlook of upper mid-single digit growth","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Preliminary Q4 2024 revenue guidance of $970M to $980M (unaudited, subject to change).","BSI segment bookings described as solid in the fourth quarter.","2025 constant exchange rate revenue growth outlook: upper mid-single digits, assuming low-single digit market growth.","Company presented at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.","Final Q4 and full-year 2024 financial statements have not yet been completed or audited."],"consensus_eps_estimate":null,"consensus_eps_actual":0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":3366400000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186915,"accession_number":"0000950170-24-121064","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bruker Q3 revenue up 16.4% but GAAP EPS $0.27 down from $0.60; FY2024 guidance lowered","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $864.4M, up 16.4% YoY; organic growth 3.1%, CER growth 15.7%.","GAAP EPS $0.27 vs $0.60 prior year; non-GAAP EPS $0.60 vs $0.74, down 18.9%.","BSI segment organic revenue grew 3.8% YoY; BEST segment organic revenue declined 3.2%.","FY2024 revenue guidance lowered to $3.34-$3.37B (organic growth 3-4%); non-GAAP EPS $2.36-$2.41.","Management cites persistent biopharma and China headwinds as reason for guidance cut."],"consensus_eps_estimate":null,"consensus_eps_actual":0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":2386800000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203456,"accession_number":"0001104659-24-086565","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Philip Ma resigns from Bruker board effective Aug 5, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Philip Ma resigned from Bruker board on August 5, 2024, effective immediately.","Resignation to concentrate efforts on his own company; not related to any disagreement with Bruker.","Company will commence a search for a replacement director to fill the vacancy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203455,"accession_number":"0000950170-24-091188","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bruker Q2 revenue $800.7M (+17.4% YoY), raises FY2024 revenue guidance to $3.38-$3.44B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $800.7M, up 17.4% YoY; organic revenue growth 7.4%.","GAAP EPS $0.05, non-GAAP EPS $0.52 (+4% YoY).","BSI segment revenue $735.6M (+19.7% YoY, organic +8.6%).","FY2024 revenue guidance raised to $3.38-$3.44B (14-16% growth), non-GAAP EPS $2.59-$2.64.","Three strategic acquisitions completed in H1 2024, including NanoString spatial biology business."],"consensus_eps_estimate":null,"consensus_eps_actual":0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":1522400000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219866,"accession_number":"0001104659-24-068698","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K/A","filed_at":"2024-06-05T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Bruker amends prior 8-K to correct clerical error in legal opinion for $67.29/share offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corrects omission of share count (6M firm shares + 900K option shares) in initial Exhibit 5.1.","Underwriting terms unchanged: $67.29 per share, BofA and J.P. Morgan as underwriters.","Offering details previously disclosed on May 31, 2024; no other changes to the 8-K.","Amendment solely replaces legal opinion; all other exhibits remain as filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219872,"accession_number":"0001104659-24-067154","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Bruker launches 6M-share offering at $67.29 to repay acquisition-related debt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 6,000,000 shares at $67.29 per share; underwriters have 30-day option for 900,000 additional shares.","Net proceeds to reduce indebtedness following recent strategic acquisitions; repay borrowings under Jan 18, 2024 credit agreement.","Joint book-runners: BofA Securities and J.P. Morgan.","Offering expected to close May 31, 2024, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219871,"accession_number":"0000950170-24-066508","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Bruker amends bylaws, adds Delaware forum clause; annual meeting votes approve directors, pay, auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Adopted amended bylaws with enhanced advance notice for shareholder nominations and proposals.","New forum selection clause designates Delaware Chancery Court for most internal claims.","All three Class III director nominees elected: Linton (105.7M for), Perkins (122.1M), Rosenthal (122.1M).","Advisory say-on-pay passed with ~96% support (120M for, 4.8M against).","Ratification of PricewaterhouseCoopers as auditor approved with 140.8M for (99.7% of votes cast)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219870,"accession_number":"0000950170-24-051560","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bruker Q1 revenue $721.7M (+5.3% YoY); GAAP EPS falls to $0.35; FY24 guidance raised $60M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $721.7M (+5.3% YoY); organic revenue up 1.6%.","GAAP diluted EPS $0.35 (down from $0.52); non-GAAP EPS $0.53 (down from $0.64).","BSI segment $651.1M (+3.9% YoY); BEST segment $73.1M (+17.5% YoY).","FY24 revenue guidance raised to $3.29-$3.35B; non-GAAP EPS guidance $2.79-$2.84.","Closed ELITech acquisition on April 30; pending NanoString acquisition not included in guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":721700000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219869,"accession_number":"0000950170-24-051559","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bruker completes €870M cash acquisition of ELITechGroup; expects $0.08-0.10 EPS accretion","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price of €870 million in cash for ELITech, excluding clinical chemistry business.","ELITech FY2023 revenue ~€150M with >80% consumables; systems include InGenius and BeGenius MDx platforms.","Remainder 2024 expected ELITech revenue ~$100M within Bruker, non-GAAP EBIT margins >20%.","Non-GAAP EPS accretion of $0.08-$0.10 for FY 2024 after acquisition financing costs.","ELITech to become Bruker Molecular Diagnostics within Microbiology & Infection Diagnostics division."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219868,"accession_number":"0001104659-24-049697","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Bruker to acquire NanoString assets for $392.6M in cash; expected to close Q2 2024","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Bruker to acquire substantially all NanoString assets for $392.6M cash, including nCounter, GeoMx, CosMx and AtoMx product lines.","NanoString 2023 revenue ~$168M; bankruptcy court approved Chapter 363 sale on April 19, 2024; close expected Q2 2024.","Deal expected dilutive to non-GAAP EPS by $0.15-$0.20 in H2 2024; near break-even by 2026 with resumed growth and synergies.","Bruker will fund with cash on hand and debt; NanoString to become part of Bruker Spatial Biology business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219867,"accession_number":"0000950170-24-039776","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Bruker enters CHF 450M term loan facilities (3/5/7-year) for general corporate purposes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered CHF 150M three-year, CHF 150M five-year, and CHF 150M seven-year term loan facilities on March 29, 2024.","Facilities are unsecured, guaranteed by certain subsidiaries; interest at SARON plus margin (1.000%-1.750% based on leverage).","Delayed draw available until Sept 30, 2024; no initial borrowing; proceeds for M&A, refinancing, working capital, capex.","Quarterly amortization starts June 2024 (3/5-yr) or June 2026 (7-yr); prepayable without penalty.","Covenants include leverage ratio test and usual representations; defaults trigger acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239627,"accession_number":"0000950170-24-014189","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bruker Q4 revenue $854.5M (+20.6%); FY 2024 organic growth 5-7%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $854.5M, up 20.6% YoY; organic revenue +15.9%.","Q4 non-GAAP EPS $0.70 (-5.4% YoY); pro forma non-GAAP EPS ex-PhenomeX $0.80 (+8.1% YoY).","FY 2023 revenue $2.96B (+17.1%); non-GAAP EPS $2.58 (+10.3% YoY).","FY 2024 guidance: revenue $3.23-3.29B (organic 5-7%), non-GAAP EPS $2.71-2.76 (5-7% growth)."],"consensus_eps_estimate":null,"consensus_eps_actual":2.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":2964500000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239626,"accession_number":"0000950170-24-013561","cik":1109354,"company_name":"BRUKER CORP","ticker":"BRKR","form_type":"8-K","filed_at":"2024-02-12T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Bruker Corp enters note purchase agreement for CHF 100M senior notes due 2036/2039","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["CHF 50M 2.60% Series A Senior Notes due April 15, 2036 and CHF 50M 2.62% Series B due April 15, 2039.","Notes are unsecured, guaranteed by certain subsidiaries; covenants include leverage ratio ≤3.50x and interest coverage ≥2.50x.","Proceeds to be used for acquisitions, refinancing of existing debt, and general corporate purposes.","Closing expected on or about April 15, 2024, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7401209924.804347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}